BACKGROUND: Radium-223 has been shown to improve overall survival in men with metastatic castration-resistant prostate cancer with symptomatic bone metastases.
The bone scan response to radium-223 has only been described in one single center trial of 14 patients, none of whom achieved the outstanding bone scan response presented in the current case.
CASE PRESENTATION: In this case report, we describe a 75 year-old white man with extensively pre-treated metastatic castration-resistant prostate cancer and symptomatic bone metastases who experienced a flare in pain and prostate-specific antigen, followed by dramatic clinical (pain), biochemical (prostate-specific antigen), and imaging (bone scan) response.
CONCLUSION: The flare phenomena and bone scan response we observed have not previously been described with radium-223. This case suggests that the degree and duration of bone scan response may be predictive of overall survival benefit.
Written by:
McNamara MA, George DJ. Are you the author?
Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA; Duke University Medical Center, 1 Trent Drive, Morris Building Rm #25169, Box 3841, Durham, NC, 27710, USA. ;
Reference: BMC Cancer. 2015 May 7;15(1):371.
doi: 10.1186/s12885-015-1390-y
PubMed Abstract
PMID: 25948240